GENEPEP
Private Company
Total funding raised: $2.5M
Overview
GENEPEP is a privately held, revenue-generating service provider and product supplier in the peptide and protein chemistry space. With over 20,000 peptides synthesized, its core expertise lies in custom synthesis, modification, and analysis of complex peptides and small proteins up to 200 amino acids. The company serves as a fee-for-service or FTE-based partner for R&D projects in drug discovery, leveraging a platform centered on solid-phase peptide synthesis and native chemical ligation.
Technology Platform
Specializes in chemical synthesis of peptides and small proteins using Solid-Phase Peptide Synthesis (SPPS) and Native Chemical Ligation (NCL). Platform includes capabilities for extensive modification (labels, non-coded amino acids, PTMs), peptide library creation, analytical services (HPLC/UPLC, MS), and grafting/linker chemistry for surface conjugation.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
GENEPEP competes in a fragmented global market for peptide synthesis services against large players like Bachem and GenScript, as well as numerous regional and low-cost CROs. Its differentiation is based on expertise in complex chemical modifications, native chemical ligation for proteins, and a strong focus on customer partnership and problem-solving, rather than competing solely on price or volume for standard peptides.